Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 2/20 | 0.54 |
| ▸ | KIF11 | P52732 | 9/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7021665 | 1.00 | CA4 (0.56) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL7030329 | 0.91 | CA1 (0.61) | CA4LTA4HCA12CA1CA2 | |
| SCHEMBL28067932 | 0.84 | CA4 (0.59) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL8858901 | 0.84 | CA4 (0.59) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL10112758 | 0.84 | CA4 (0.59) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL14856630 | 0.84 | CA4 (0.59) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL5051055 | 0.84 | CA4 (0.59) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL8648265 | 0.84 | CA4 (0.59) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL1286989 | 0.84 | CA4 (0.59) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL4570566 | 0.82 | CA4 (0.56) | CA4LTA4HKIF11KCNH2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720039-A2 | FORMULATIONS CONTAINING TRYPTAMINE DERIVATIVES AND USES THEREOF | Psilera Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| WO-2024243488-A2 | FORMULATIONS CONTAINING TRYPTAMINE DERIVATIVES AND USES THEREOF | PSILERA INC. (US) | 2024-11-28 | — | — | WO | claimed |
| US-20040185459-A1 | Diagnostic nucleotide/protein sequences for monitoring and identifying restriction fragment length polymorphisms | GENOX RESEARCH, INC. (JP) | 2004-09-23 | — | — | US | disclosed |
| US-20030055297-A1 | An alkyl, cycloalkyl, arylalkyl dihydroxy compound useful as intermediates; a cost-effective preparation | ABBOTT LABORATORIES | 2003-03-20 | — | — | US | disclosed |
| WO-2002081441-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRROLIDINE NEURAMINIDASE INHIBITORS | ABBOTT LABORATORIES (US) | 2002-10-17 | — | — | WO | disclosed |
| EP-0305201-B1 | Protected biotin derivatives | ZENECA LTD (GB) | 1996-12-04 | — | — | EP | disclosed |
| US-5247081-A | Labeled polynucleotide probes used as diagnostic tools for clinical and research uses | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-09-21 | — | — | US | disclosed |
| EP-0305201-A2 | Protected biotin derivatives | ZENECA LIMITED (GB) | 1989-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040185459-A1 | Diagnostic nucleotide/protein sequences for monitoring and identifying restriction fragment length polymorphisms | UNG, DCLRE1B, FEN1 | CA4 3413/4885LTA4H 3996/4885KIF11 3614/4885 |
| US-20030055297-A1 | An alkyl, cycloalkyl, arylalkyl dihydroxy compound useful as intermediates; a cost-effective preparation | NEU4, NEU2, NEU1 | CA4 570/4885LTA4H 309/4885KIF11 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.